Table 2.
Molecular markers of indolent MCL
| Ki-67 index ≤ 30% |
| CD200 positivity |
| No TP53 mutation/deletion |
| Lack of SOX11 |
| Without rearrangement and overexpression of MYC |
| IGHV mutations |
| L-MCL16 assay and MCL35 assay |
| Unmutated P16 status |
| Without/minimal defects of ATM |
| No NOTCH1/2 mutation |
| Amp 11q gene mutation |
| No chr9 deletion |
| Several genes that have been valued in recent years (all of them are weakly expressed) |
| SPEN |
| SMARCA4 (SWI/SNF) |
| RANBP2 |
| KMT2C |
| NSD2 (WHSC1) |
| CARD11 |
| FBXW7 |
| BIRC3 |
| KMT2D (MLL2) |
| CELSR3 |
| TRAF2 |
| MAP3K14 |
| HNRNPH1 |
| Del 9p and /or Del 9q |
| SP140 |
| PCDH10 |
| Genes that lack data |
| Kappa light chain restriction |
| Almost no incidence of frameshift Bax mutations |
| CD34 (−/ ±), CD83(−/ ±) |
| No expression of HMG |
| PARP1 silencing |
| Up-regulation of BACH2 |
| Cluster 1 methylation pattern with somatic mutation |
| Inhibition of Akt pathway |
| No loss of PTEN |
| Without overexpression of Mcl-1 |
| MicroRNAs upregulation/downregulation |